• Explore /
  • Poster
  • / A phase 2 study of the WEE1 inhibitor AZD1775 in <em>SETD2</em>-deficient advanced solid tumor malignancies.

A phase 2 study of the WEE1 inhibitor AZD1775 in SETD2-deficient advanced solid tumor malignancies.

Abstract Poster

Authors

Edward Maldonado

Edward Maldonado

University of California San Francisco, San Francisco, CA

Edward Maldonado , Wendy Kimryn Rathmell , Geoffrey Shapiro , Jordi Rodon Ahnert , Devalingam Mahalingam , Nikolaos Trikalinos , Arash Rezazadeh , Victor Ricardo Adorno Febles , Mamta Parikh , Scott Anthony Boerner , Gregor Krings , Naoko Takebe , Patricia LoRusso , Rahul Raj Aggarwal

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

Small Molecules

Clinical Trial Registration Number

NCT03284385

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 3104)

DOI

10.1200/JCO.2023.41.16_suppl.3104

Abstract #

3104

Poster Bd #

302

Abstract Disclosures

Similar Posters

First Author: Scott S. Tykodi

First Author: David R. Spigel

First Author: Laurence Albiges

First Author: Eric Jonasch